Körlük, Sirkadiyen Ritim Uyku Bozukluğu ve Terapötik Yaklaşımlar
Özet
Kör insanlarda oküler ışık algısının olmaması, hipotalamustaki suprakiazmatik nükleusta bulunan sirkadiyen saatin senkronizasyonunu bozarak melatonin ve kortizol salgılanması ile uyku-uyanıklık döngülerinin intrinsik periyoduna dönmesine neden olmaktadır. Bu durum, kör bireylerin yarısından fazlasında görülen, gece uykusuzluğu ve gündüz aşırı uyku hali ile karakterize "24 saat olmayan uyku-uyanıklık ritim bozukluğu" başta olmak üzere ciddi sirkadiyen ritim bozukluklarına yol açar. Teşhis sürecinde aktigrafi, uyku günlükleri ve bir melatonin metaboliti olan 6-sülfatoksimelatoninin (aMT6s) biyolojik ölçümleri kullanılarak tanı kesinleştirilir. Tedavi yaklaşımında öncelikle sosyal rutinlerin, beslenme saatlerinin ve fiziksel aktivitelerin düzenlenmesini içeren ilaç dışı, fotik olmayan alternatif zamanlayıcılar (zeitgeber) tercih edilir. İkinci basamakta ise sirkadiyen saati faz kayması yoluyla 24 saatlik döngüye sürüklemek amacıyla kronobiyotik etkili ekzojen melatonin uygulaması veya sirkadiyen fazı etkilediği FDA tarafından onaylanmış güçlü bir melatonin reseptör agonisti olan Tasimelteon kullanılır. İlaçların kullanım zamanlaması ve süresi sirkadiyen saatin başarıyla sıfırlanmasında kritik bir öneme sahiptir. Sonuç olarak, görme engelli bireylerin sosyal ve profesyonel yaşam kalitelerini doğrudan etkileyen bu sirkadiyen ritim bozukluklarında klinik farkındalığın artırılması, erken tanı konulması ve çok boyutlu terapötik yaklaşımların hızla başlatılması hayati bir önem taşımaktadır.
The absence of ocular light perception in blind individuals disrupts the synchronization of the circadian clock located in the suprachiasmatic nucleus of the hypothalamus, causing melatonin and cortisol secretion along with sleep-wake cycles to revert to their intrinsic periods. This situation leads to severe circadian rhythm disorders, particularly "non-24-hour sleep-wake rhythm disorder," which is observed in more than half of totally blind individuals and characterized by night insomnia and excessive daytime sleepiness. In the diagnostic process, the diagnosis is confirmed using actigraphy, sleep diaries, and biological measurements of 6-sulfatoxymelatonin (aMT6s), a melatonin metabolite. In the treatment approach, non-pharmacological, non-photic alternative synchronizers (zeitgebers) including the regulation of social routines, meal times, and physical activities are preferred first. In the second line, exogenous melatonin administration with chronobiotic effects or Tasimelteon, a potent melatonin receptor agonist approved by the FDA to affect the circadian phase, is used to entrain the circadian clock to a 24-hour cycle through phase shifting. The timing and duration of medication use are of critical importance in successfully resetting the circadian clock. Consequently, raising clinical awareness, achieving early diagnosis, and rapidly initiating multidimensional therapeutic approaches are of vital importance in these circadian rhythm disorders that directly affect the social and professional life quality of visually impaired individuals.
Referanslar
Yıldız S, Gürler S. The Assessment of Information Levels of People with Visual Impairment in Terms of Their Disabled Rights- The Case of Ankara-. Kırıkkale Üniversitesi Sosyal Bilimler Dergisi. 2018; 8(1): 241-268.
Hebebci, M. T. Görme Engelli ve az gören bireyler için geliştirilen donanım ve yazılımlar. Bilim, Eğitim, Sanat ve Teknoloji Dergisi (BEST Dergi). 2017; 1(2): 52-62.
Hankins MW, Peirson SN, Foster RG. Melanopsin: an exciting photopigment. Trends Neurosci. 2008; 31(1): 27–36.
Quera Salva MA, Hartley S, Léger D, et al. Non-24-Hour Sleep–Wake Rhythm Disorder in the Totally Blind: Diagnosis and Management. Frontiers in Neurology. 2017; 8. doi:10.3389/fneur.2017.00686
Lockley SW, Skene DJ, Arendt J, et al. Relationship between melatonin rhythms and visual loss in the blind. J Clin Endocrinol MetaB. 1997; 82(11): 3763–70.
Lockley SW, Skene DJ, Butler LJ, et al. Sleep and activity rhythms are related to circadian phase in the blind. Sleep. 1999; 22(5): 616–23.
Lockley SW, Dijk DJ, Kosti O, et al. Alertness, mood and performance rhythm disturbances associated with circadian sleep disorders in the blind. J Sleep Res. 2008; 17(2): 207–16.
Lerner AB, Case JD, TakahashiI Y. Isolation of melatonin and 5- methoxyindole-3-acetic acid from bovine pineal glands. J Biol Chem.1960; 235: 1992–7.
Dubocovich ML, Markowska M. Functional MT1 and MT2 melatonin receptors in mammals. Endocrine. 2005; 27(2):101–10. doi:10.1385/ENDO: 27:2:101
Alarma-Estrany P, Pintor J. Melatonin receptors in the eye: location, second Messenger sandrolein ocular physiology. Pharmacol Ther. 2007; 113(3): 507–22. doi:10.1016/j. pharmthera.2006.11.003
Launay JM, Lamaître BJ, Husson HP, et al. Melatonin synthesis by rabbit platelets. Life Sci. 1982; 31(14): 1487–94. doi:10.1016/0024-3205(82)90010-8
Dubocovich ML, Delagrange P, Krause DN, et al. International union of basic and clinical pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors. Pharmacol Rev. 2010; 62(3): 343–80. doi:10.1124/pr.110.002832
Mailliet F, Ferry G, Vella F, et al. Characterization of the melatoninergic MT3 binding site on the NRH:quinone oxidoreductase 2 enzyme. Biochem Pharmacol. 2005; 71(1–2): 74–88. doi:10.1016/j. bcp.2005.09.030
Nosjean O, Ferro M, Coge F, et al. Identification of the melatonin-binding site MT3 as the quinone reductase 2. J Biol Chem. 2000; 275(40): 31311–7. doi:10.1074/jbc.M005141200
Lockley SW, Arendt J, Skene DJ. Visual impairment and circadian rhythm disorders. Dialogues in Clinical Neuroscience. 2007; 9(3): 301-314. DOI: 10.31887/DCNS.2007.9.3/slockley
Kleitman N. Sleep and Wakefulness. Chicago, Ill: University of Chicago Press; 1963.
Roelfsema, F. The influence of light on circadian rhythms. Experientia 1987; 43: 7-13.
Skene DJ, Lockley SW, Thapan K, et al. Effects of light on human circadian rhythms. Reprod Nutr Dev. 1999; 39: 295-304.
Flynn-Evans EE, Tabandeh H, Skene JD, et al. Circadian Rhythm Disorders and Melatonin Production in 127 Blind Women with and without Light Perception. Journal of Biological Rhythms. 2014; 29(3): 215–224.
Mistlberger RE, Skene DJ. Nonphotic entrainment in humans? J Biol Rhythms. 2005; 20: 339-352.
Mazzoni F, Novelli E, Strettoi E. Retinal ganglion cells survive and maintain normal dendritic morphology in a mouse model of inherited photoreceptor degeneration. J Neurosci. 2008; 28: 14282-14292.
Medeiros NE, Curcio CA. Preservation of ganglion cell layer neurons in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2001; 42: 795-803.
Zaidi FH, Hull JT, Peirson SN, et al. Short-wavelength light sensitivity of circadian pupillary and visual awareness in humans lacking an outer retina. Curr Biol. 2007; 17: 2122-2128
Tabandeh H, Lockley SW, Buttery R, et al. Disturbance of sleep in blindness. Am J Ophthalmol. 1998; 126(5): 707–12. doi:10.1016/S0002-9394(98)00133-0
Lockley SW, Dressman MA, Licamele L, et al. Tasimelteon for non-24-hour sleep-wake disorder in totally blind people (SET and RESET): two multicentre, randomised, double-masked, placebo-controlled phase 3 trials. Lancet. 2015; 386(10005): 1754–64. doi:10.1016/ S0140-6736(15)60031-9
American Assocation of Sleep Medicine. International Classification of Sleep Disorders Version 3 (ICSD-3). Darien, IL: American Assocation of Sleep Medicine. 2014.
Flynn-Evans EE, Lockley SW. A pre-screening questionnaire to predict non24-hour sleep-wake rhythm disorder (N24HSWD) among the blind. J Clin Sleep Med. 2016; 12(5): 703–10. doi:10.5664/jcsm.5800
Sack RL, Brandes RW, Kendall AR, et al. Entrainment of free-running circadian rhythms by melatonin in blind people. N Engl J Med. 2000; 343 (15) : 1070–7. doi:10.1056/ NEJM 2000101 23431503
Moog R, Endlich H, Hildebrandt G, et al. Chronobiology & Chronomedicine: Basic Research and Applications. Frankfurt am Main, Germany: Verlag Peter Lang; 1987:439-44
Morgenthaler TI, Lee-Chiong T, Alessi C, et al. for the Standards of Practice Committee of the AASM. Practice parameters for the clinical evaluation and treatment of circadian rhythm sleep disorders. An American Academy of Sleep Medicine report. Sleep. 2007; 30: 1445–1459
Lewy AJ, Ahmed S, Jackson JM, et al. Melatonin shifts human circadian rhythms according to a phase-response curve. Chronobiol Int. 1992; 9(5): 380–392.
Cagnacci A, Elliott JA, Yen SS. Melatonin: a major regulator of the circadian rhythm of core temperature in humans. J Clin Endocrinol Metab. 1992; 75(2): 447–52. doi:10.1210/jc.75.2.447
Cajochen C, Kräuchi K, Wirz-Justice A. Role of melatonin in the regulation of human circadian rhythms and sleep. J Neuroendocrinol. 2003; 15(4): 432–7.doi:10.1046/j.1365-2826.2003.00989.x
Cajochen C, Kräuchi K, Wirz-Justice A. The acute soporific action of daytime melatonin administration: effects on the EEG during wakefulness and subjective alertness. J Biol Rhythms. 1997; 12(6): 636–43. doi:10.1177/074873049701200619
Eastman, C. Entraining the free-running circadian clocks of blind people. The Lancet. 2015; 386(10005): 1713–1714. doi:10.1016/s0140-6736(15)61451-9
Rajaratnam SM, Polymeropoulos MH, Fisher DM, et al. Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials. Lancet. 2009; 373(9662):482–91. doi:10.1016/S0140-6736(08)61812-7
Ferguson SA, Rajaratnam SM, Dawson D. Melatonin agonists and insomnia. Expert Rev Neurother. 2010; 10: 305–18
Tasimelteon (Hetlioz) for non-24-hour sleep-wake disorder. Med Lett Drugs Ther. 2014; 56: 34–35.
